Somewhat surprising outcome, IMO, and possibly a Pyrrhic victory insofar as Bayer will have a hard time getting individual EU countries to reimburse Xarelto for the ACS indication.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.